Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based clinical stage biopharmaceutical company developing donor-derived, cell-based allogeneic immunotherapies for cancers. This news page aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how CytoMed’s gamma delta T cell and iPSC-derived platforms progress from research into clinical application.
According to its public communications, CytoMed is advancing a Phase I CAR gamma delta T cell trial in Singapore (the ANGELICA Trial), supporting a Phase II Investigator-Initiated Trial in India, and preparing a first-in-human trial in Malaysia for unmodified allogeneic γδ T cells in collaboration with Universiti Malaya. News items frequently cover milestones such as completion of dose levels in the ANGELICA Trial, memoranda of understanding with hospital partners, and publications of collaborative research with institutions like The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia.
Investors and observers can also find updates on CytoMed’s corporate developments, including the build-out of its cord blood-derived platform under subsidiary LongevityBank, the acquisition of a licensed cord blood bank in Malaysia, and non-dilutive investment into LongevityBank. Additional announcements may describe asset acquisitions related to T cell technologies, at-the-market equity programs, and changes in significant shareholdings.
For those tracking GDTC, this news feed provides a centralized view of CytoMed’s progress in oncology-focused cell therapies, its expansion into cord blood-derived and regenerative applications, and its evolving strategy in Southeast Asia, India and China. Regularly reviewing these updates can help readers understand how the company’s clinical, scientific and corporate activities develop over time.
CytoMed Therapeutics (NASDAQ: GDTC) reported its full-year 2024 financial results, showing improved performance with a reduced net loss of $1.85 million, a 39% improvement from 2023's $3.03 million loss. The company's topline income reached $624,771 in 2024, up from $588,423 in 2023.
Key financial highlights:
- Cash balance: $3.64 million as of December 31, 2024
- Research expenses: $1.40 million, up from $1.16 million in 2023
- Employee benefits: $453,321, increased from $332,413 in 2023
Notable clinical developments include the launch of the ANGELICA Trial, a first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells. The company expanded operations by acquiring a licensed cord blood bank in Malaysia and is preparing for clinical trials in India. CytoMed plans to establish a New York liaison office and expects sufficient cash runway through 2026, while exploring potential funding opportunities for growth and acquisitions.
CytoMed Therapeutics (NASDAQ: GDTC) released a chairman's letter highlighting key achievements in 2024 and outlining plans for 2025. The company, based in Singapore and Malaysia, specializes in producing affordable GMP-grade immune cells for cancer and autoimmune disease treatment.
Key 2024 accomplishments include: becoming a clinical-stage biopharma with the initiation of the ANGELICA trial, the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells; acquiring a licensed cord blood bank for US$450,000; establishing strategic collaborations in China and India; advancing iPSC-derived hybrid immune cell development; and participating in an AI project for infectious diseases treatment.
For 2025, CytoMed plans to: release initial ANGELICA trial results by mid-year; submit a US FDA IND for their allogeneic gamma delta T cells; establish presence in New York; and implement revenue-generating methods through compassionate use programs. The company reports having over one year of cash runway from their US$10 million NASDAQ IPO.
CytoMed Therapeutics (NASDAQ: GDTC) has signed a Business & Research Collaboration Agreement with India's SunAct Cancer Institute to conduct a Phase 2 clinical trial investigating allogeneic gamma delta T cells for cancer treatment. The collaboration aims to explore the safety, tolerability, and efficacy of CytoMed's proprietary cell therapy for various solid tumors.
The accelerated trial, combining Phase 1 and Phase 2, will be jointly sponsored by both companies and led by Prof Dr Vijay Patil at SunAct Cancer Institute. CytoMed will provide scientific support and manufacture the investigational product, while SunAct contributes local expertise and access to India's healthcare infrastructure.
The five-year agreement leverages India's supportive regulatory environment through CDSCO and aims to provide affordable cancer treatment options. The collaboration aligns with CytoMed's strategy to develop cost-effective, donor-derived cell-based immunotherapies for cancer treatment.
CytoMed Therapeutics (NASDAQ: GDTC) has announced the dosing of its first patient in the ANGELICA Trial, a Phase I clinical trial evaluating allogeneic NKG2DL-targeting CAR gamma delta T cells (CTM-N2D) for advanced solid tumors and hematological malignancies. This marks the company's transition to a clinical-stage biopharma. Unlike traditional CAR-T therapy that uses patient's own cells, CytoMed's approach uses donor blood-derived gamma delta T cells, which can be used without donor-patient matching. This method aims to improve cell quality, reduce production costs, and increase therapy accessibility.
CytoMed Therapeutics (NASDAQ: GDTC) has received full approval for its first-in-human Phase I ANGELICA clinical trial using patented allogeneic CAR-T cell therapy against blood and solid tumors. The trial, conducted in collaboration with the National University Hospital of Singapore, is co-funded by the NMRC Clinical Trial Grant. Unlike traditional CAR-T therapies, CytoMed's approach uses gamma delta T cells from healthy donors, potentially improving quality, lowering costs, and increasing accessibility.
Additionally, CytoMed has completed a cash acquisition of a licensed cord blood bank in Malaysia, expanding its strategy into cord blood-derived biologics through its subsidiary, LongevityBank Pte This acquisition provides access to cord blood donated for research and development, supporting CytoMed's focus on cell therapies for aging diseases and regenerative medicine.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking licence and assets through its subsidiary, IPSC Depository Sdn Bhd. The acquisition includes a licence from Malaysia's Ministry of Health, cryopreservation equipment with over 12,000 cord blood units, and two freehold properties. This move expands CytoMed's strategy in cell therapies, providing access to rare cord blood for research and development in regenerative medicine and aging diseases.
The new biotechnology arm will be operated through CytoMed's subsidiary, LongevityBank Pte . Evelyn Tan, CEO of IPSC Depository Sdn Bhd, stated that this acquisition aims to unlock the therapeutic potential of umbilical cord blood, targeting longevity and wellness. CytoMed's co-CEO, Dr Tan Wee Kiat, highlighted the synergy between CytoMed and IPSC Depository in deriving immune gamma delta T cells from cord blood to fight cancers.
CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has reported its financial results for the six months ended June 30, 2024, and provided clinical updates. The company is focused on developing novel donor-derived, cell-based allogeneic immunotherapies for cancer treatment.
Key highlights include:
- Ongoing recruitment for the ANGELICA Trial, a first-in-human Phase I clinical trial for allogeneic CAR-γδ T cells (CTM-N2D)
- Net loss of S$1.09 million (US$803,235) for the period
- Cash and bank balances of S$6.47 million (US$4.78 million) as of June 30, 2024
- Research and development expenses increased to S$974,402 (US$719,010)
- General and administrative expenses decreased to S$902,910 (US$666,256)
The company is progressing with its proprietary technologies and has scheduled a conference call for October 8, 2024, to discuss the results further.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking license and assets from Cellsafe International for approximately US$490,000. The acquisition includes cryopreservation equipment with over 12,000 cord blood units and two freehold properties. This move strengthens CytoMed's position in allogeneic gamma delta (γδ) T cell technology for cancer treatment.
Additionally, CytoMed has been granted a new patent in Malaysia for its iPSC-derived hybrid γδ NKT cells technology, expanding its tumor-targeting therapy patent portfolio. The company aims to develop cytotoxic γδ T cells from three sources: adult peripheral blood mononuclear cells, induced Pluripotent Stem Cells, and cord blood.
CytoMed plans to repurpose cord blood units for a wider range of therapies, including solid cancer treatment. The company is currently conducting the ANGELICA Trial, a phase 1 clinical trial in Singapore focused on CAR-T therapy.
Summary not available.
Summary not available.